Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAGON: Ravulizumab and OCS Tapering in gMG
NCT07221838Phase 4Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 4 trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07221838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221838.